Cahill Represents Lead Arrangers In Halozyme Therapeutics’ $750 Million Credit Facility

Cahill represented the lead arrangers in connection with an amendment to Halozyme Therapeutics, Inc.'s credit agreement to extend the maturity and increase the revolving credit facility by $175 million to $750 million.

Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes.